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Abstract
Background: High incidence of septic patients increases the pressure of faster and more reliable bacterial identification
methods to adapt patient management towards focused and effective treatment options. The aim of this study was to
assess two automated DNA extraction solutions with the PCR and microarray-based assay to enable rapid and reliable
detection and speciation of causative agents in the diagnosis of sepsis.
Methodology/Principal Findings: We evaluated two automated DNA instruments NucliSENSH easyMAGH and NorDiag
Arrow for the preparation of blood culture samples. A set of 91 samples flagged as positive during incubation was analyzed
prospectively with the high-throughput generation of Prove-it
TM Sepsis assay designed to identify over 60 Gram-negative
and Gram-positive bacterial species as well as methicillin resistance marker from a blood culture. Bacterial findings were
accurately reported from 77 blood culture samples, whereas 14 samples were reported as negative, containing bacteria not
belonging to the pathogen panel of the assay. No difference was observed between the performance of NorDiag Arrow or
NucliSENSH easyMAGH with regard to the result reporting of Prove-it
TM Sepsis. In addition, we also assessed the quality and
quantity of DNA extracted from the clinical Escherichia coli isolate with DNA extraction instruments. We observed only minor
differences between the two instruments.
Conclusions: Use of automated and standardized sample preparation methods together with rapid, multiplex pathogen
detection offers a strategy to speed up reliably the diagnostics of septic patients. Both tested DNA extraction devices were
shown to be feasible for blood culture samples and the Prove-it
TM Sepsis assay, providing an accurate identification of
pathogen within 4,5 hours when the detected pathogen was in the repertoire of the test.
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Introduction
Sepsis is a life-threatening disease, associated with high rates of
morbidity and mortality. It is estimated that 4 million out of 13
million septic patients die worldwide each year [1]. Time to
diagnosis for sepsis and an early initiation of effective antimicrobial
therapy has been a major predictor of an outcome of a septic
patient [2,3,4]. Kumar and colleagues (2006) demonstrated a
strong relationship between the delay in initiation of antimicrobial
therapy and reduced survival. The risk for death in septic patients
increased 7,6% per hour after the first six hours of documented
hypotension. Thus, an early identification of the causative agent is
crucial and often informative enough for directing treatment
decisions towards an evidence-based antimicrobial therapy [5,6].
Currently, blood culture is the gold standard of diagnosis for
sepsis. The method is based on cultivation and detection of viable
micro-organisms present in blood. The presumptive pathogen
classification from a positive blood culture is first concluded on the
basis of morphological features and cell wall characteristics of the
microbe by Gram-staining. Positive blood culture is subcultured
further on different growth media and a set of phenotypic tests are
run for a characterization and identification of the microbe. The
definitive identification of pathogens is usually achieved within one
to three days after the blood culture is flagged as positive, but may
take even longer for atypical and fastidious organisms. Culture is at
the moment the only possibility for determining the antimicrobial
susceptibility of the pathogen. These methods are time-consuming
and highly manual procedures, which delay efficient, pathogen-
driven patient management [7,8,9].
Many novel molecular strategies have emerged to speed up
diagnosis for sepsis. One of the recently introduced approaches is a
combination of PCR and microarray. The main advantages of
microarray over other DNA-based approaches are broad
pathogen coverage, the potential to differentiate closely related
microbial species accurately, and simultaneous identification of
multiple microbes in the single reaction [10,11,12].
The Prove-it
TM Sepsis assay, consisting of a broad-range PCR
and microarray-based platform (Mobidiag, Finland) has been
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blood cultures. Tissari and co-workers (2010) [13] indicated the
assay to be 99% specific and 95% sensitive, with a pathogen panel
covering over 50 clinically relevant bacterial species as well as the
methicillin resistance marker. They also concluded that the assay
was on average one day faster than the culture-based gold
standard and could thus enable earlier evidence-based manage-
ment for clinical sepsis. The newest generation of the assay is the
high-throughput Prove-it
TM StripArray platform having 8 well
strips and containing one microarray at the bottom of each well.
This microarray platform allows parallel analysis of 1 to 96
samples in one run.
When adapting a PCR-based protocol in a routine clinical
setting, a prerequisite for a sensitive analysis is the efficient
preanalytical sample preparation step, including DNA extraction.
Hence, these steps should always be evaluated carefully, especially
in respect to cell wall disruption of a microbe and subsequent
recovery of microbial DNA without putative PCR inhibitors
originated from the clinical sample. In recent years, a number of
DNA extraction instruments have become available to response to
the needs of faster and labor-efficient solutions. Automated DNA
extraction allows for simultaneous preparation of a high number of
samples with reduced hands-on time and human errors, thus
improving precision, reproducibility and traceability [14,15,16,
17].
The aim of the study was to bring together novel technologies
for faster sepsis diagnostics; automated DNA extraction to be used
in conjunction with the PCR and microarray-based bacterial
identification method. We evaluated the Prove-it
TM Sepsis
StripArray platform together with in vitro diagnostic labeled
NucliSENSHeasyMAGH (bioMe ´rieux, France) and NorDiag
Arrow (NorDiag, Norway) extraction instruments. These plat-
forms utilize magnetic particle based extraction technology. Both
instruments were also compared for their relative efficiency in
recovering and purifying bacterial DNA from the clinical E.coli
isolate and their technical aspects of usability.
Results
Evaluation of DNA extraction instruments using blood
culture samples
We evaluated the functionality and suitability of the NucliSENSH
easyMAGH and NorDiag Arrow extraction instruments for
sepsis diagnostics together with the Prove-it
TM Sepsis assay,
using positive blood culture material. In total, 91 samples
flagged as positive during the blood culture incubation from
patients suspected with sepsis were collected in two weeks time
in October, 2009. The samples were not consecutive. Tissari
and co-workers (2010) extracted DNA from over 3300 blood
culture samples, using the NucliSENSHeasyMAGH instruments
with the starting volume of 100 ml and the elution volume of
55 ml. These volumes were also used in this study, but the
volumes of NorDiag Arrow were adjusted according to the
recommendations of the used Arrow VIRAL NA kit, using the
starting volume of 250 ml and the elution volume of 100 ml.
The DNA extracts of blood culture samples were analyzed with
the Prove-it
TM Sepsis assay. The PCR and microarray-based
results showed the perfect concordance in bacterial identifications
between DNA extracts of both instruments (Table 1). Among
the 91 positive blood culture samples, 41 (45,1%) Gram-
negative and 32 (35,2%) Gram-positive bacteria were detected.
In addition, four (4,4%) polybacterial and 14 (15,4%) negative
samples were reported. The most commonly identified bacteria
were Escherichia coli (29,7%), coagulase negative staphylococci
other than Staphylococcus epidermidis (CNS, 9,9%), S. epidermidis
(6,6%), and Klebsiella pneumoniae (5,5%). The negative results were
achieved from non-target pathogens, such as Streptococcus viridans
and anginosus group, Moraxella osloensis, Capnocytophaga canimorsus,
and Micrococcus sp. The bacteria found represent well the overall
distribution of blood culture findings in this laboratory.
Correlation between Prove-it
TM Sepsis and the reference
results
We compared the bacterial identification results of blood culture
samples analyzed with the Prove-it
TM Sepsis assay to those of the
reference method. Overall, the results between the two methods
were similar. In case of 12 conflicting results (Table 2), the blood
culture samples were subjected further to test repeating, DNA
sequencing and/or more data were obtained from HUSLAB in
order to study more closely the bacterial species in question.
In one pair of aerobic and anaerobic bottles from the reference
method E. coli was reported, whereas the PCR and microarray
assay reported Enterobacteriaceae group. We sequenced the 59region
of the gyrB gene of these samples and conducted homology
searches and sequence comparisons against the public (EBI and
NCBI) and proprietary sequence databases. The sequences
showed relative 96% (381/398 bp) similarity to the gyrB sequence
of E.coli, but the similarity was not enough to make a definitive
conclusion of the species found. Two samples from the same
patient that were reported as Streptococcus pyogenes by the reference
method shared 100% homology with the gyrB gene region of
Streptococcus dysgalactiae subsp. equisimilis which was reported by the
PCR and microarray assay. The strain, however, represented
Lancefield group A antigen, which is by definition the prerequisite
for indentifying S. pyogenes. The sequencing also confirmed the
PCR and microarray-based speciation of two Staphylococcus
epidermidis samples which were originally identified as CNS. From
one sample, the reference method identified CNS when the PCR
and microarray assay reported a negative result. The sequencing
result specified the CNS species to be Staphylococcus capitis, which
was not included in the CNS taxon of the PCR and microarray
assay; therefore, the reported results were regarded as concordant.
Streptococcus pneumoniae was identified from two samples, two
anaerobic bottles, by the PCR and microarray assay, when the
reference method reported negative result in the other sample and
S. pneumoniae was detected by Accuprobe hybridization test
(GenProbe, USA) from the other sample. The confirmatory probe
hybridisation test was performed due to pathognomonic staining
result; poorly stained, autolysed coccoid bacterial structures
detected both in Gram-staining and acridine orange staining.
In three samples, the PCR and microarray-based results were
not completely accurate. From one polybacterial sample, the assay
identified organisms Enterococcus faecalis, Enterococcus gallinarum,
Proteus vulgaris, but failed to detect Enterococcus faecium. Staphylococcus
aureus and CNS were reported from one sample, whilst the
reference method reported only CNS. The sequencing specified
CNS species to be Staphylococcus capitis. Most probably, the strain
variation and excess amount of amplicons led to cross-hybridiza-
tion with S.aureus oligonucleotide probes, resulting in false positive
identification of S. aureus. Contamination due to human error also
caused one false positive identification of Enterococcus faecalis by the
PCR and microarray assay.
On the basis of bacterial identification and additional data
comparison, including sequencing results, we concluded that
96.7% (88/91) of the samples were speciated correctly by the
Prove-it
TM Sepsis assay, including 14 negatively reported findings
from non-target pathogens.
Microarray Assay and DNA Extraction for Sepsis
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Three subsamples of E. coli suspensions with the assigned OD600
values of 3, 2, 1, 0.1, and 0.01 were extracted parallel with
NucliSENSHeasyMAGH and NorDiag Arrow, after which the
yields and purity (A260/280) of DNA extracts were compared by the
means of spectrophotometer and real-time PCR analysis.
DNA yields from the samples with a higher cell density, i.e.
samples with the assigned OD600 values of 3, 2, and 1 were
measured to be between 15–30 ng/ml by a spectrophometer,
whereas the samples with a lower cell density, i.e. samples with the
assigned OD600 values of 0.1 and 0.01 were measured to be
,5 ng/ml. The means of DNA concentrations from the three
parallel subsamples extracted with the both instruments were
approximately at the same level (Figure 1). However, we found
differences between the tested DNA extraction instruments when
we compared the standard deviations between triplicates from the
assigned OD600 values of 3, 2, 1, 0.1, and 0.01. DNA
concentrations from the triplicates varied slightly when DNA
extraction was performed with NorDiag Arrow.
On average, the A260/280 ratios of 1,2 to1,5 were measured for
the samples with the assigned OD600 values of 3, 2, and 1 and the
A260/280 ratios of 0,6 to 1,1 for the samples with the assigned
OD600 values of 0.1 and 0.01 (Figure 2). The similar variation in
standard deviations as detected with DNA yields was also found
when we examined the purity of the triplicate samples extracted
with NorDiag Arrow. In contrast, triplicates extracted with the
NucliSENSHeasyMAGH showed smaller deviations in the mea-
sured values of DNA concentration and purity.
The DNA extracts were also subjected to the real-time PCR of
the E. coli chromosomal d-1-deoxyxylulose 5-phosphate synthase
gene (dxs) [18] for the comparison of the cycle threshold (Ct)-
values. In general, higher Ct-values reaching over 20 were
associated with lower DNA concentrations (,5 ng/ml) measured
by a spectrophotometer and vice versa with higher DNA
Table 1. Comparison of identifications of various agents identified from the blood culture (BC) samples with respect to the used
DNA extraction solutions of NucliSENSHeasyMAGH and NorDiag Arrow.
Identified bacteria by Prove-it
TMAdvisor
Number
of samples
Propotion of
BC samples (%)
Concordance of bacteria identifications between
DNA extracts of NucliSENSHeasyMAGH and
NorDiag Arrow (%)
Gram-negative bacteria
Bacteroides fragilis group 2 2,2 100
Enterobacter cloacae 1 1,1 100
Enterobacteriaceae group 2 2,2 100
Escherichia coli 27 29,7 100
Haemophilus influenzae 1 1,1 100
Klebsiella peumoniae 5 5,5 100
Proteus mirabilis 1 1,1 100
Pseudomonas aeruginosa 1 1,1 100
Serratia marcescens 1 1,1 100
TOTAL 41 45,1
Gram-positive bacteria
CNS 9 9,9 100
Enterococcus faecalis 3 3,3 100
Propionibacterium acnes 1 1,1 100
Staphylococcus aureus 4 4,4 100
Staphylococcus epidermidis 6 6,6 100
Streptococcus agalactiae 2 2,2 100
Streptococcus dysgalactiae subsp. equisimilis 3 3,3 100
Streptococcus pneumoniae 4 4,4 100
TOTAL 32 35,2
Polybacterial identifications
Enterococcus faecalis, Enterococcus gallinarum,
Proteus vulgaris
1 1,1 100
Enterococcus faecalis, Staphylococcus epidermidis 1 1,1 100
Staphylococcus aureus, CNS 1 1,1 100
Staphylococcus aureus, Staphylococcus epidermidis 1 1,1 100
TOTAL 4 4,4
No organism detected
Negative 14 15,4 100
TOTAL 91 100
doi:10.1371/journal.pone.0026655.t001
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TM Sepsis categorized
on the basis of reported results.
Reported results
Prove-it
TMSepsis Reference method Number of samples Confirmed speciation
Enterobacteriaceae group Escherichia coli 2 Enterobacteriaceae group
Enterococcus faecalis, Enterococcus
gallinarum, Proteus vulgaris
Enterococcus faecalis, Enterococcus
gallinarum/casseliflavus, Proteus vulgaris,
Enterococcus faecium
1 Enterococcus faecalis, Enterococcus
gallinarum, Proteus vulgaris,
Enterococcus faecium
Enterococcus faecalis,
Staphylococcus epidermidis
Staphylococcus
epidermidis
1 Staphylococcus epidermidis,
Negative CNS, Streptococcus
viridans group
1 Staphylococcus capitis, Streptococcus
viridans group
Staphylococcus aureus, CNS CNS 1 Staphylococcus capitis
Staphylococcus epidermidis CNS 2 Staphylococcus epidermidis
Streptococcus dysgalactiae
subsp. equisimilis*
Streptococcus pyogenes 2 Streptococcus dysgalactiae subsp.
equisimilis*
Streptococcus pneumoniae Negative 2 Streptococcus pneumoniae
TOTAL 12
*Streptococcus dysgalactiae subsp. equisimilis expressing also the Lancefield’s serogroup A.
doi:10.1371/journal.pone.0026655.t002
Figure 1. Comparison of the DNA yields of extracted E.coli DNA. Average values and their standard deviations of the three replicated
subsamples of E.coli DNA extracts are presented in the columns. Columns are classified by the optical density values (OD600) of the E.coli suspensions
measured prior to DNA extraction. DNA concentrations (ng/ml) were measured by a spectrophotometer and Cycle treshold (Ct) -values are based on
the real-time PCR.
doi:10.1371/journal.pone.0026655.g001
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DNA concentrations measured by a spectrophotometer showed a
wider range than the Ct-values obtained during real-time PCR
runs. Thus, the similar kind of deviations obtained by a
spectrophotometer was not found from the Ct-values. Otherwise,
the yield measurements and Ct-values of real-time PCR were in
accordance.
Technical comparison of the NucliSENSHeasyMAGH and
NorDiag Arrow instruments
The NucliSENSHeasyMAGH and NorDiag Arrow instruments
were also compared for the technical aspects. The technical
analysis included the comparison of flexibility in sample and
elution volumes, a total DNA extraction time and the number of
sample per run (Table 3). The analysis was conducted based on
the kits and the programs used in this study.
Discussion
In this study, we assessed the performance of a newest
generation of Prove-it
TM Sepsis assay, incorporating the bacterial
detection of proven performance [13] into the high-throughput
platform. The accurate identification was demonstrated by
analyzing 91 positive blood culture samples. We compared the
obtained PCR and microarray-based results with those of the
reference method, observing only 12 (13,2%) conflicting identi-
fications, of which DNA sequencing confirmed nine PCR and
microarray results. Three remaining discrepant results were
either due to contamination while processing the sample, or
Figure 2. Comparison of the purity (A 260/280) of extracted E.coli DNA. Average values and their standard deviations of the three replicated
subsamples of E.coli DNA extracts are presented in the columns. Columns are classified by the optical density values (OD600) of the E.coli suspensions
measured prior to DNA extraction. Purity of the extracts was determined by a spectrophotometer.
doi:10.1371/journal.pone.0026655.g002
Table 3. Comparative analysis of the technical aspects of NucliSENSHeasyMAGH and NorDiag Arrow.
aNucliSENSHeasyMAGH (bioMe ´rieux)
bNorDiag Arrow (NorDiag)
Samples per one run 1–24 1–12
Total turnaround time (min) (including lysis
step, excluding hands-on time)
50 (10 min for lysis step, 40 min for extraction step) 58
Sample volume (ml) 10 to 1000 250, 550
Eluation volume (ml) 25 to 110, in 5 ml increments 100
aGeneric 2.0.1 protocol.
bArrow VIRAL NA kit and the Viral 010 program.
doi:10.1371/journal.pone.0026655.t003
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missing reporting of E. faecium from the polybacterial samples,
consisting of E. faecalis, E. faecium, E. gallinarum, and P. vulgaris.F o r
other polybacterial samples, the identifications were correct.
When the additional information and sequencing results were
taken into account we concluded that the bacterial speciations
with the PCR and microarray were correct in 96,7% of the
analyzed samples when the analysis was limited to those bacteria
covered by the assay. Similar figure has been detected in earlier
studies [13,19].
Of note was that S. pyogenes was identified from two samples of
one patient by the reference method, but the PCR and microarray
assay reported S. dysgalactiae subsp. equisimilis findings from both
samples, which were also confirmed by the sequencing. Pyogenic
streptococci are divided into serogroups based on their Lancefield
group antigens. S. dysgalactiae subsp. equisimilis usually exhibits the
Lancefield’s serogroup C or G antigens, whereas S. pyogenes
exhibits the serogroup A. The used reference method exploited the
serotyping of streptococci in the species identification. Similar
results to those in this study were also noticed by Brandt and co-
workers (1999) [20], who studied in detail the clinical blood culture
isolates of S. dysgalactiae subsp. equisimilis expressing also the
Lancefield’s serogroup A. These isolates share virulence determi-
nants with S.pyogenes, thus emphasizing the importance of both
Lancefield grouping as well as biochemical data. The DNA-based
methods may be of assistance in accurate speciation of beta-
hemolytic streptococci.
DNA-based methods are also preferred in cases when blood
culture samples are reported as false negatives due to the autolysis
of microbes or in the case of fastidious organisms. This was most
likely the case when S. pneumoniae was identified by the PCR and
microarray assay, but a negative result was reported by the
reference method. S. pneumoniae is known to have a tendency to
undergo autolysis when it reaches the stationary phase of growth
[21] and therefore, it cannot always be reported by the
conventional blood culture-based method.
We studied the isolates identified as E.coli by the reference
method and Enterobacteriaceae by the PCR and microarray assay in
great detail. The sequencing of the conserved 59 gene region of
topoisomerase gene gyrB showed 96% homology to that of E. coli,
showing sequence variation at many nucleotide positions untypical
for E.coli. We also sequenced the gyrB gene regions of Escherichia
fergusonii and Escherichia hermannii, possessing similar phenotypic
characters as E.coli, and also related to misidentification of E.coli
[22]. However, the sequences of these species were not similar
with the isolate in question. Also, the homology searches against
the sequence databases did not reveal higher homology to any
other bacterial species. Therefore, we concluded that the isolate
could belong to the Escherichia taxon, but was not E. coli. In the
study of Tissari and colleague (2010), also four similar blood
culture isolates with 97–98% homology with the E. coli gyrB
sequence were observed (data not published). Although these
results are interesting in terms of bacterial taxonomy, we
acknowledge that in these cases the misidentification of E. coli
would have little or no clinical significance.
In response to recognized limitations of the current gold
standard method of sepsis diagnostics, several new diagnostic
strategies have been emerged [23]. The requirements for new
clinical diagnostics of sepsis include automated, labor-efficient
solutions that provide accurate diagnostic results in a timely
manner. Typically, DNA-based technologies involve three con-
secutive steps: nucleic acid extraction, amplification and detection
together with data analysis. Various automated nucleic acid
extraction devices have been spread to the field of DNA-based
sepsis diagnostics [24]. The performance of the DNA extraction
solution impacts on the sensitivity and success of subsequent
downstream analysis. In this study, we brought together two
aspects of novel technologies for sepsis diagnostics; automated
sample preparation together with multiplex DNA-based identifi-
cation of causative bacterial agents.
We evaluated the performance of two automated DNA
extraction instruments NucliSENSHeasyMAGH and NorDiag
Arrow for the preparation of blood culture samples prior to the
Prove-it
TM Sepsis analysis. Both DNA extraction instruments
efficiently lysed the microbes and seemed to remove the possible
PCR inhibitors. The PCR and microarray-based results obtained
from the DNA extracts of blood culture samples were in perfect
accordance when the results from the two instruments were
compared. The bacteria from which DNA were extracted
consisted of nine clinically relevant Gram-negative and 10
Gram-positive bacterial species. Among the Gram-positive
bacteria were commonly encountered species in sepsis, such as
Staphylococcus and Streptococcus spp, possessed a rigid cell wall which
can be difficult to lyse [25].
In addition to the qualitative bacterial identification compari-
son, we also conducted quantitative analysis by comparing yields
and purity of DNA extracts of clinical isolate of E.coli. DNA yields
of the eluates of both instruments were comparable in samples
originated from the same E. coli suspension. However, minor
deviations were found in the concentrations of the eluates of three
parallel samples extracted with NorDiag Arrow. The variability of
the standard deviations was wider when the concentrations were
measured by a spectrophotometer, but such a variation was not
found so strongly from Ct-values determined by a real-time PCR
assay. In general, the A260/280 ratios of the measured DNA
extracts did not reach the optimal purity value of 1.8. We noticed
that the low cell density in the starting volume prior to the
extraction correlated in lower A260/280 ratios values measured.
A260/280-ratios are linearly reduced by the increasing protein
concentration and other contaminants putatively found in DNA
extracts, having absorbance in the region 230 nm to 320 nm. The
measurement of the DNA concentration out in the optimal purity
range of DNA, i.e. the A260/280-ratios of 1.5–2.0, should be
regarded only as suggestive [26]. Furthermore, we cannot rule out
the limitations of the spectrophotometer measurements.
The other perspective of usability of the extraction instruments
to the diagnostic procedures is to take a short view for the
NucliSENSHeasyMAGH and NorDiag Arrows technical aspects
(Table 3). In general, advantages of the NucliSENSHeasyMAGH
are flexibility, like highly adjustable starting and elution volumes
and capability to handling various sample types with the same
reagent kit. Also, 1–24 samples can be run simultaneously in the
instrument. However, depending on the number of samples
analyzed in a routine basis, a smaller bench-top instrument
capable of running up to 12 samples, like NorDiag Arrow can be
sufficient enough for diagnostics, especially if the instrument
provides cost-efficient purchasing and running costs. The turn-
around times of the instrument were similar, less than one hour.
We considered that the platforms were robust, easy-to-use and
require little hands-on-time, allowing more effective use of
resources.
In conclusion, NucliSENSHeasyMAGH and NorDiag Arrow
DNA extraction devices were shown to be efficient and feasible for
preparation of blood culture samples when used in conjunction
with the Prove-it
TM Sepsis assay. The accurate identification of
pathogens was available within 4,5 hours in the same day as the
blood culture flagged as positive. New diagnostics assays are
needed for the prompt and reliable identification of causative
Microarray Assay and DNA Extraction for Sepsis
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appropriate, pathogen-driven antimicrobial therapy. This study
shows that an integration of automated and standardized sample
preparation method together with a PCR and microarray-based
assay into patient management pathways provides the solution
that decreases hands-on-time while increasing accuracy, robust-
ness, and traceability. Moreover, the combination offers faster
diagnosis of septic patients than the current conventional culture-
based diagnostics, which in turn has the potential to lead to
positive outcomes.
Materials and Methods
Samples
Blood culture material and reference method. A total of
91 blood culture samples flagged as positive from patients with
suspected sepsis were collected in the Department of Bacteriology,
HUSLAB, Finland, during the two weeks of October in 2009.
Blood samples taken into aerobic and anaerobic blood culture
bottles of BacT/AlertH (bioMe ´rieux, France) were incubated in the
blood culturing instrument BacT/ALERT 3 D (bioMe ´rieux) for
up to 5–6 days until they were reported as negative if no sign of
microbial growth was detected. If possible growth was observed,
the microbe was conventionally speciated and the results represent
the reference method in this study. Gram-staining, and when
necessary, acridine orange staining, were performed on all flagged
samples. Biochemical tests for bacterial identification and
antibiotic susceptibility testing were performed according to the
CLSI guidelines (http://www.clsi.org). These analyses were
primarily performed directly from an aliquot of the blood
culture sample. Additional biochemical or molecular biology
tests were performed when necessary. Typically, it took one to two
days to identify the microbe from a positive blood culture.
Clinical isolate. Clinical isolate of Escherichia coli, provided
by HUSLAB, was aerobically cultured on a blood agar for 24 h at
37uC. Cultured bacteria were suspended to the 16 phosphate
buffered saline (PBS) buffer (Jena Bioscience GmbH, Germany)
and the optical density (OD) of a bacterial suspension at 600 nm
was measured by a spectrophotometer (BioPhotometer,
Eppendorf). Bacterial suspensions with assigned OD600 values of
3, 2, 1, 0.1 and 0.01 were prepared. Each suspension was divided
into three parallel subsamples (triplicates) prior to DNA extraction.
DNA extraction
DNA extraction was performed using both NucliSENSHeasy-
MAGH (www.biomerieux.com) and NorDiag Arrow (www.nor-
diag.com) instruments. NucliSENSHeasyMAGH was used accord-
ing to the Generic 2.0.1 protocol, having a starting volume of
100 ml and an elution volume of 55 ml with the blood culture
material. In parallel, NorDiag Arrow was used according to the
Arrow VIRAL NA kit and the Viral 010 program, having a
starting volume of 250 ml and an elution volume of 100 ml. In case
of clinical isolates, the starting volume was 250 ml and the elution
volume was 100 ml with the both instruments.
PCR and microarray assay
DNA extracts of blood culture samples were analyzed by the
Prove-it
TM Sepsis StripArray assay (Mobidiag, Finland), according
to the manufacturer’s instructions. Briefly, the Prove-it
TM Sepsis
assay was based on broad-range PCR and microarray technologies
and designed to identify bacterial pathogens in positive blood
cultures [13,19]. The proprietary primers were used for the
amplification of specific regions of the bacterial topoisomerase
genes gyrB and parE [27], and the methicillin resistance gene mecA.
For the amplification step, the MastercyclerH epgradient S thermal
cycler (Eppendorf, Germany) was used.
The amplicons were subsequently introduced onto the micro-
array area of the Prove-it
TM StripArray. Positive hybridization-
based reactions were detected and reported by the StripArray
Reader and the Prove-it
TM Advisor analysis software (version 1.0).
The target identification was interpreted using specific built-in
rules and parameters of the Prove-it
TM Advisor software. Prior to
the result reporting, the internal control probes of the assay,
evaluating mainly the functionality of the PCR and hybridization
steps were required to pass the built-in rules. The result consisted
of the name(s) of identified bacterial target(s) and detailed
information about data, such as signal intensities and number of
identified oligonucleotide probes. The DNA extraction and PCR
controls included in each test series were required to be negative
for the acceptance of a particular test series.
DNA sequencing
For sequencing, various sets of specific primers originated from
gyrB gene region were applied. Sequencing was performed using
cycle sequencing with Big Dye Terminator kit (version 3.1,
Applied Biosystems, USA) and reactions were run on ABI 3130xl
capillary sequencer according to the manufacturer’s instructions.
For sequence homology searches, BLAST algorithm [28] against
the European Bioinformatics database (www.ebi.ac.uk/Tools), the
National Center for Biotechnology Information database (blas-
t.ncbi.nlm.nih.gov/Blast.cgi), and the proprietary sequence data-
base of Mobidiag was applied. The definitions of the bacterial
species were made on the bases of the sequence homology with the
known bacterial species of these used databases.
Quality and quantity determination
After parallel DNA extraction with NucliSENSHeasyMAGH and
NorDiag Arrow, quality of subsamples of E.coli suspensions (OD600
values of 3, 2, 1, 0.1, and 0.01) were studied by spectrophotometer
measurements and real-time PCR. 1 ml of extracted DNA was
pipetted to the NanoDrop spectrophotometer (Thermo Fisher
Scientific, USA), which reported the DNA concentration and purity
of nucleic acids (A260/280). The real-time PCR designed for the E.
coli chromosomal d-1-deoxyxylulose 5-phosphate synthasegene (dxs)
[18] was conducted, applying a SYBR Green I dye –based assay
and Stratagene Mx3000P Q-PCR System with Stratagene MxPro
Q-PCR Software, version 4.10 (Agilent Technologies, USA). The
PCR mixture was prepared using Brilliant II SYBR Green Q-PCR
kit (Agilent Technologies, USA): 16Brilliant II SYBR Green Q-
PCR master mix, 30 nM Reference dye, forward primer F (59-
CGAGAAACTGGCGATCCTTA-39) and reverse primer R (59-
CTTCATCAAGCGGTTTCACA-39) at a final concentration of
1 mM (Metabion, Germany), 2 ml of isolated DNA and PCR-grade
water to bring total volume to 15 ml. The thermal cycling protocol
was as follows: initial denaturation for 10 min at 95uC followed by
40 cycles of 15 sec at 95uC, 1 min at 54uC and 1 min at 72uC,
continuing to the one cycle of 15 sec at 95uC, 1 min at 60uCa n d
15 sec at 95uC for the dissociation curve analysis. At the end of the
run, the software produced the dissociation curve and amplification
plots together with the cycle threshold (Ct) -values for the further
analysis.
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